Medicortex Finland is dedicated to improving the diagnosis, treatment and prevention of acute neurodegenerative
conditions, and is currently focused on developing a novel multiplex treatment for traumatic brain injury (TBI) as well as brain injury due to stroke.

Business Strategy

Medicortex is focusing on identifying and capturing a biomarker for TBI and stroke. Our vision is to incorporate this into a quick, inexpensive and easy-to-use test to be used as a quick diagnosis tool and to help establish the existence of a mild brain trauma. Medicortex's novel, multi-functional approach at treating TBI and stroke aims at decreasing circulating toxic metal ion levels in the brain and at minimizing oxidation by free radicals. This synergistic approach is expected to block the neurodegenerative cascade.

Medicortex is determined to become a revolutionary biotech company. Today, no accurate diagnosis for TBI exists, and diagnosis is based on neurological evaluation and imaging methods that are not always sufficient. A quick and easy test based on one of the body fluids would help doctors in the diagnosis in emergency response situations. 

Moreover, there is no competent neuro-protective medication for brain injury, which is one of the largest and most serious unmet medical needs in the world today. We firmly believe that our pipeline represents by far the most logical approach to meeting that dire medical need. The time to move forward is now. Many statistical studies have indicated that TBI and ABI (Acquired Brain Injury) are both on the rise, and not simply because of population growth. Be it increasing longevity, private automobile use, sports and recreation participation or soldiering, the burden of brain injury is only going to rise in the coming years – and Medicortex will be at the forefront of finding a solution.